Literature DB >> 11595612

Torsades de pointes caused by Mibefradil.

S Gläser1, M Steinbach, C Opitz, U Wruck, F X Kleber.   

Abstract

We report a case of symptomatic Torsades de pointes due to QTc prolongation by Mibefradil, which potentially explains unexpected deaths related to this drug. Multiple episodes of Torsades de pointes were documented in a 76-year-old woman with significant QTc prolongation of 0.53 s. After discontinuation of Mibefradil QTc intervals normalized and no further ventricular tachyarrythmias were observed. We conclude that Mibefradil can cause QTc prolongation and life threatening ventricular dysrhythmias.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11595612     DOI： 10.1016/s1388-9842(01)00159-3

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


  4 in total

Review 1.  Development of newer calcium channel antagonists: therapeutic potential of efonidipine in preventing electrical remodelling during atrial fibrillation.

Authors:  Narutaka Ohashi; Hideo Mitamura; Satoshi Ogawa
Journal:  Drugs       Date:  2009       Impact factor: 9.546

2.  Equivalence and noninferiority trials - are they viable alternatives for registration of new drugs? (III).

Authors:  Cornel Pater
Journal:  Curr Control Trials Cardiovasc Med       Date:  2004-08-17

3.  Regulation of aldosterone secretion by Cav1.3.

Authors:  Catherine B Xie; Lalarukh Haris Shaikh; Sumedha Garg; Gizem Tanriver; Ada E D Teo; Junhua Zhou; Carmela Maniero; Wanfeng Zhao; Soosung Kang; Richard B Silverman; Elena A B Azizan; Morris J Brown
Journal:  Sci Rep       Date:  2016-04-21       Impact factor: 4.379

Review 4.  Targeting Ca2 + Handling Proteins for the Treatment of Heart Failure and Arrhythmias.

Authors:  Alexandra Njegic; Claire Wilson; Elizabeth J Cartwright
Journal:  Front Physiol       Date:  2020-09-04       Impact factor: 4.566
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.